ReviewVascular health and risk management2018
Anemia and acute coronary syndrome: current perspectives.
Review in Vascular health and risk management, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 77 citations in OpenAlex.
- Liberal versus restrictive red blood cell transfusion strategy in acute coronary syndrome and anemia: an updated systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2025Pooled it
- Impact of anemia on acute ischemic stroke outcomes: A systematic review of the literature.PloS one · 2023Pooled it
- Article
- Opportunistic CT Attenuation Biomarkers of Anemia Are Associated With Impaired Myocardial Flow Reserve and Cardiovascular Outcomes.medRxiv : the preprint server for health sciences · 2026Article
- Clinical Profile and Outcomes of Patients with Chronic Kidney Disease on Chronic Hemodialysis Hospitalized for Acute Coronary Syndrome in a Tertiary Public Hospital in the Philippines.Acta medica Philippina · 2026Article
- The Effect of Iron Deficiency Anemia on the Morphology-Voltage-P Wave Duration (MVP) Risk Score.Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc · 2025Article
- The Negative Influence and Adverse Outcome of Red Blood Cell Transfusion in Contemporary Percutaneous Coronary Interventions.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2025Review
- Impact of sodium-glucose transport protein-2 (SGLT2) inhibitors on the inflammasome pathway in acute myocardial infarction in type 2 diabetes mellitus: a comprehensive review.Cardiovascular diabetology · 2025Review
- Pre-percutaneous coronary intervention hemoglobin as a prognostic indicator for 6-month mortality in acute myocardial infarction patients: a secondary analysis of the Korea Acute Myocardial Infarction Registry National Institutes of Health cohort.Journal of thoracic disease · 2025Article
- Trends in hemoglobin-to- red cell distribution width ratio and its prognostic value for all-cause, cancer, and cardiovascular mortality: a nationwide cohort study.Scientific reports · 2025Article
- Interaction between anemia and renal dysfunction in relation to long-term survival following acute myocardial infarction.Clinical research in cardiology : official journal of the German Cardiac Society · 2024Article
- Mechanisms and treatment of anemia related to cardiac arrest.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2024Review
- Article
- Restrictive Blood Transfusion Policy for the Management of Anemia in Palliative Care in Finland.Palliative medicine reports · 2024Article
- Impact of Anemia and Acquired Anemia on in-Hospital Mortality of Acute Coronary Syndrome Patients.International journal of general medicine · 2024Article
- Dual Antiplatelet Therapy and Cancer; Balancing between Ischemic and Bleeding Risk: A Narrative Review.Journal of cardiovascular development and disease · 2023Review
- Risk stratification algorithm for clinical outcomes in anemic patients undergoing percutaneous coronary intervention.Annals of medicine · 2023Article
- Risk Factors Analysis for Hemoglobin Decline Caused by Diagnostic Blood Collection in Respiratory Department in North China: A Case-Control Study.International journal of general medicine · 2023Article
- Relevance of pre-existing anaemia for patients admitted for acute coronary syndrome to an intensive care unit: a retrospective cohort analysis of 7418 patients.European heart journal open · 2022Article
- The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey.Annals of hematology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reference hemoglobin (Hb) values for the definition of anemia are still largely based on the 1968 WHO Scientific Group report, which established a cutoff value of <13 g/dL for adult men and <12 g/dL for adult nonpregnant women. Subsequent studies identified different normal values according to race and age. Estimated prevalence of anemia on admission in the setting of an acute coronary syndrome (ACS) is between 10% and 43% of the patients depending upon the specific population under investigation. Furthermore, up to 57% of ACS patients may develop hospital-acquired anemia (HAA). Both anemia on admission and HAA are associated with worse short- and long-term mortality, even if different mechanisms contribute to their prognostic impact. Baseline anemia can usually be traced back to preexisting disease that should be specifically investigated and corrected whenever possible. HAA is associated with clinical characteristics, medical therapy and interventional procedures, all eliciting cardiovascular adaptive response that can potentially worsen myocardial ischemia. The intrinsic fragility of anemic patients may limit aggressive medical and interventional therapy due to an increased risk of bleeding, and could independently contribute to worse outcome. However, primary angioplasty for ST elevation ACS should not be delayed because of preexisting (and often not diagnosed) anemia; delaying revascularization to allow fast-track anemia diagnosis is usually feasible and justified in non-ST-elevation ACS. Besides identification and treatment of the underlying causes of anemia, the only readily available means to reverse anemia is red blood cell transfusion. The adequate transfusion threshold is still being debated, although solid evidence suggests reserving red blood cell transfusions for patients with Hb level <8 g/dL and considering it in selected cases with Hb levels of between 8 and 10 g/dL. No evidence supports the use of iron supplements and erythropoiesis-stimulating agents in the setting of ACS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.